Q4 and full-year results showed strong operational activity, with higher prices offsetting lower volumes in several segments. Despite lower quotas and biological challenges, profitability was supported by robust market demand and improved margins in key areas.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.